Utilization of liver allografts from donors older than 60 in Israel: Benefits and risks

Transplantation Proceedings

Volumn 29, Issue 7, 1997, Pages 3079-3080

  Mor, E ^a,b   Shmueli, D ^a   Bar Nathan, N ^a   Sharabani, E ^a   Yussim, A ^a   Ben Ari, Z ^a   Tur Kaspa, R ^a   Shapira, Z ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; STEROID;

ADULT; ALLOGRAFT; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE SEVERITY; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; ISRAEL; LIVER TRANSPLANTATION; ORGAN DONOR; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; GRAFT SURVIVAL; HUMANS; ISRAEL; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TISSUE DONORS;

EID: 0030728788     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(97)00791-4     Document Type: Conference Paper

References (6)

1. Ploeg RJ, D'Alessandro AM, Hoffmann RM, et al: Transplant Proc 25:3031, 1993
2. Adam R, Sanchez C, Astarcioglu I, et al: Transplant Proc 27:1181, 1995
3. Wall WJ, Mimeault R, Grand DR, et al: Transplantation 49:377, 1990
4. Nakazato PZ, Concepcion W, Bry W, et al: Surgery 111:37, 1992
5. Marino IR, Doyle HR, Doria C, et al: Transplant Proc 27:1184, 1995
6. Strasberg SM, Howard TK, Molmenti EP, et al. Hepatology 20:829, 1994